# Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome

Study · id `cardio:ct-nct05298475` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05298475](<https://clinicaltrials.gov/study/NCT05298475>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05298475

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05298475. Non-randomized; no masking; primary purpose treatment. Start 2022-04-01 (anticipated); primary completion 2023-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05298475, source copy `cardio:ctgov-nct05298475-2022-03-28`, retrieved 2026-10-31)
- Planned start: 2022-04-01 (anticipated) (ClinicalTrials.gov record NCT05298475, source copy `cardio:ctgov-nct05298475-2022-03-28`, retrieved 2026-10-31)
- Primary completion: 2023-04-01 (anticipated) (ClinicalTrials.gov record NCT05298475, source copy `cardio:ctgov-nct05298475-2022-03-28`, retrieved 2026-10-31)
- Completion: 2024-04-01 (anticipated) (ClinicalTrials.gov record NCT05298475, source copy `cardio:ctgov-nct05298475-2022-03-28`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT05298475, source copy `cardio:ctgov-nct05298475-2022-03-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05298475-2022-03-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Statin
- Intervention (Drug): PCSK9 inhibitor
- Intervention (Drug): PCSK9 inhibitor
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)

## Provenance

Content hash: 0789f43bfa63ce556a7a583bdbb5b6ac85092bb12c6f41dce30db93bc2457bb8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
